23andMe Garners $115,000,000 Series E Financing

  • Feed Type
  • Date
    10/14/2015
  • Company Name
    23andMe
  • Mailing Address
    1390 Shorebird Way Mountain View, CA 94043 USA
  • Company Description
    23andMe is focused on empowering individuals to access, explore, and better understand their genetic information, making use of recent advances in DNA analysis technologies and proprietary web-based software tools.
  • Website
    http://www.23andme.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $115,000,000
  • Transaction Round
    Series E
  • Proceeds Purposes
    This round of funding will enable us to further our vision for long term growth in our consumer and therapeutic businesses. This investment will enable the company to expand its operations and maximize the potential of its direct-to-consumer product in the US and abroad. The company expects to launch a new user experience that includes carrier status reports in the US, as well as enhanced tools and functionality for customers by the end of the year. The Series E financing will also provide capital for strategic infrastructure including new laboratory space for therapeutic research, a next generation sequencing laboratory as well as other investments in long-term growth.
  • M&A Terms
  • Venture Investor
    Fidelity Management & Research Company
  • Venture Investor
    Casdin Capital
  • Venture Investor
    WuXi PharmaTech
  • Venture Investor
    Xfund
  • Venture Investor
    Illumina
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    MPM Capital
  • Venture Investor
    Google Ventures

Trending on Xconomy